Clinical therapies for patients in subtypes of non-severe aplastic anemia

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900027553

Enrollment

Unknown

Registered

2019-11-18

Start date

2019-11-28

Completion date

Unknown

Last updated

2019-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-severe aplastic anemia

Interventions

early NSAA:Cyclosporine

moderate NSAA1:Cyclosporine

moderate NSAA2:Cyclosporine+Danazol

TD NSAA:CSA+TPO+G-CSF

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Diagnosis of the non-severe aplastic anemia (NSAA), including early NSAA, moderate NSAA and transfusion-dependent NSAA; 2. Aged >=18 years; 3. Eastern Cooperative Oncology Group (ECOG) performance status 0-2.

Exclusion criteria

Exclusion criteria: 1. Previous or current malignancy; 2. Severe impairment and infection of the organ (renal, hepatic, cardiac, pulmonary); 3. Severe psychiatric disorder; 4. Concurrent thrombocytopenia of other etiologies (e.g., MDS, PNH); 5. Systemic treatment with any of the medication or immunosuppressive therapy within 4 weeks before Day 1.

Design outcomes

Primary

Measure	Time frame
overall response rate;	—

Secondary

Measure	Time frame
incidence of the adverse event;	—

Countries

China

Contacts

Public ContactShi Jun

Institute of Hematology & Hospital of Blood Diseases, Chinese Academy of Medical Sciences

shijun@ihcams.ac.cn+86 13920307855

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026